News - Targretin, Tropical diseases

Filter

Popular Filters

1 to 25 of 50 results

AstraZeneca in licensing deal for MALT1 inhibitors; closes Bangalore R&D site

AstraZeneca in licensing deal for MALT1 inhibitors; closes Bangalore R&D site

31-01-2014

Belgium-based VIB, a non-profit research institute in life sciences, and the Center for Drug Design and…

Asia-PacificAstraZenecaIndiaInflammatory diseasesOncologyPharmaceuticalResearchTropical diseases

Takeda collaboration with Medicines for Malaria Venture

Takeda collaboration with Medicines for Malaria Venture

26-12-2013

Japan’s largest drugmaker Takeda Pharmaceutical has entered into agreements with Medicines for Malaria…

DSM265ELQ300PharmaceuticalResearchTakeda PharmaceuticalsTropical diseases

FDA “Breakthrough Therapy” designation for GSK’s malaria drug tafenoquine; EU Cervarix news

FDA “Breakthrough Therapy” designation for GSK’s malaria drug tafenoquine; EU Cervarix news

22-12-2013

The US Food and Drug Administration has granted “Breakthrough Therapy” designation for tafenoquine,…

CervarixEuropeGlaxoSmithKlineNorth AmericaPharmaceuticalRegulationtafenoquineTropical diseases

IFPMA and the Global Fund collaborate to help protect patients from fake medicines

05-12-2013

The International Federation of Pharmaceutical Manufacturers and Associations and the Global Fund to…

Anti-viralsAntibiotics and Infectious diseasesGlobalMarkets & MarketingPharmaceuticalRegulationTropical diseases

Novartis researchers identify new drug target for malaria

Novartis researchers identify new drug target for malaria

28-11-2013

Scientists at Swiss pharma major Novartis have discovered a new drug target for treating malaria, with…

NovartisPharmaceuticalResearchTropical diseases

New malaria vaccines roadmap targets next generation products by 2030

New malaria vaccines roadmap targets next generation products by 2030

14-11-2013

The world should aim to have vaccines which reduce malaria cases by 75%, and are capable of eliminating…

HealthcarePharmaceuticalResearchRest of the WorldTropical diseasesVaccines

US FDA delays approval of Paladin’s Impavido

US FDA delays approval of Paladin’s Impavido

12-11-2013

Canada-based specialty pharmaceutical company Paladin Labs says that the US Food and Drug Administration…

ImpavidoNorth AmericaPaladin LabsPharmaceuticalRegulationTropical diseases

Eisai enters agreement to develop treatments for neglected tropical diseases

Eisai enters agreement to develop treatments for neglected tropical diseases

11-11-2013

Eisai (TYO: 4523) has entered into a global agreement with the Broad Institute to jointly discover and…

Asia-PacificEisaiNorth AmericaPharmaceuticalResearchTropical diseases

Vaccine confers long-term protection against cholera

17-10-2013

A clinical study published in the Lancet Infectious Diseases demonstrates for the first time that an…

PharmaceuticalSanofiShanthaTropical diseasesVaccines

New data support GSK plan to file for approval of malaria vaccine in 2014

New data support GSK plan to file for approval of malaria vaccine in 2014

08-10-2013

Results from a large-scale Phase III trial, presented today at the Multilateral Initiative on Malaria…

GlaxoSmithKlinePharmaceuticalRegulationResearchRTS,STropical diseasesVaccines

Eisai gains WHO prequalification for DEC; launches high-dose Aricept in Korea

27-08-2013

Japanese drug major Eisai (TYO: 4523) has received prequalification from the World Health Organization…

AriceptAsia-PacificdiethylcarbamazineEisaiMarkets & MarketingNeurologicalPharmaceuticalRegulationTropical diseases

US orphan designation for DengueCide

12-08-2013

USA-based drug developer NanoViricides (OTC BB: NNVC) says that DengueCide, its drug candidate for the…

DengueCideNanoViricidesNorth AmericaPharmaceuticalRegulationTropical diseases

Annual approvals of new drugs for neglected diseases nearly doubled since early 2000s and 2009-12; Tufts

14-07-2013

The annual number of new drug approvals worldwide to treat neglected diseases has nearly doubled in recent…

Anti-viralsPharmaceuticalRegulationResearchTropical diseases

Novartis licenses technology to India's BioE to deliver affordable typhoid vaccines

08-07-2013

Swiss pharma major Novartis (NOVN: VX) said this morning (July 8) that it has entered into a development…

Biological E LtdLicensingNovartisPharmaceuticalResearchTropical diseasesVaccines

UNITAID market power results in price cuts of up to 80% for HIV/AIDS, TB and malaria products

30-05-2013

UNITAID's approach to transform health product markets has delivered price reductions of up to 80% for…

Anti-viralsAntibiotics and Infectious diseasesGenericsGlobalHealthcarePharmaceuticalPricingTropical diseases

Sanofi and PATH launch large-scale production of semi-synthetic artemisinin in Italy

12-04-2013

French drug major Sanofi (Euronext: SAN) and non-profit global health organization PATH's Drug Development…

artemisininPharmaceuticalProductionSanofiTropical diseases

Valeant Pharma buys US rights to Eisai's Targretin for $65 million upfront

21-02-2013

Canada's Valeant Pharmaceuticals International (TSX: VRX) says that it has acquired US rights for Targretin…

EisaiLicensingNorth AmericaOncologyPharmaceuticalTargretinValeant Pharmaceuticals

News briefs: Novartis drops Ruvise MAA; B-MS settlement; Germany donates to Global Fund

25-01-2013

The European Medicines Agency says it has been formally notified by Swiss drug major Novartis (NOVN:…

Anti-viralsBMS-986094Bristol-Myers SquibbFinancialLegalNovartisPharmaceuticalRare diseasesRegulationRuviseTropical diseases

New executive director of the Global Fund outlines ambitious agenda

21-01-2013

Mark Dybul yesterday took charge as executive director of the Global Fund to Fight AIDS, Tuberculosis…

Anti-viralsAntibiotics and Infectious diseasesFinancialManagementPharmaceuticalTropical diseases

New report shows major increase in pharmaceutical R&D for neglected diseases

16-01-2013

R&D, health system capacity-strengthening efforts, and medicine donations comprise the pharmaceutical…

GlobalPharmaceuticalRare diseasesResearchTropical diseases

PATH MVI links with Inovio on malaria vaccines and delivery technology

07-01-2013

The USA-based PATH Malaria Vaccine Initiative (MVI) has announced a follow-on collaboration with drugmaker…

Inovio PharmaceuticalsPharmaceuticalResearchTropical diseasesVaccines

1 to 25 of 50 results

Back to top